Shilpa Medicare has received EIR (Establishment Inspection Report) from US Food and Drug Administration (USFDA) to both API manufacturing facilities located at Raichur, Karnataka. This inspection was carried out on January 16-19, 2018. The inspection has now been closed by USFDA.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.